The Patent Finder

Terms ending in 2033

Astellas Pharma Inc.

Every in-force patent on Astellas Pharma Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,085,540Pyrazinecarboxamide Compound
In force
 · High confidence
Astellas Pharma Inc.In forceHigh confidence
US 9,127,055Method of Treating Pain with Anti-Human NGF Antibody
In force
 · High confidence
Astellas Pharma Inc.In forceHigh confidence
US 9,481,911Methods for Detecting FGFR3/TACC3 Fusion Genes
In force
 · High confidence
Astellas Pharma Inc.In forceHigh confidence
US 10,004,739Methods for Treating Cancer by Inhibiting FGFR3/TACC3 Fusion Protein
In force
 · High confidence
Astellas Pharma Inc.In forceHigh confidence
US 9,447,090Imidazopyridine Compounds
In force
 · High confidence
Astellas Pharma Inc.In forceHigh confidence
US 9,433,675Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer
In force
 · High confidence
Astellas Pharma Inc.In forceHigh confidence
US 10,022,444Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer
In force
 · High confidence
Astellas Pharma Inc.In forceHigh confidence
US 10,813,996Combination Therapy Involving Antibodies Against Claudin 18.2 for Treatment of Cancer
In force
 · Low confidence
Astellas Pharma Inc.In forceLow confidence
US 11,839,689Formulations of Enzalutamide
In force
 · Low confidence
Medivation Prostate Therapeutics LLCIn forceLow confidence
US 12,447,128Formulations of Enzalutamide
In force
 · High confidence
Astellas Pharma Inc.In forceHigh confidence
3 more term ends in 2033 · Pro
10 of 13 patents shown. Soonest term end first, then patent number.
Pro members see all 13.
Upgrade to Pro
11 of these are in force and held by Astellas Pharma Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited